McKesson Raises FY EPS Guidance to $44.20–$45.00, Wellverse Profit Drops 20%
MCK sits 27% above its 52-week low of $687.68 on elevated volume (2.6× avg).
Summary
McKesson raised fiscal EPS guidance by $0.40 to $44.20–$45.00, implying 13–15% reported and 15–17% adjusted growth. Wellverse Medical-Surgical sales rose ~4% but adjusted operating profit fell ~20% on product mix and one-time costs. An IPO of Wellverse is planned for H2 2027, market permitting. This follows strong Q1 results and the $2.25B Precision Medicine acquisition announced in August. The guidance raise is modest but confirms momentum; the Wellverse profit decline is a watch item ahead of the planned separation.
At the time of this announcement, MCK was trading at $875.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $102B. The 52-week trading range was $687.68 to $999.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.